The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”). Viatris investors have until June 3, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR VIATRIS INC. INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On December 23, 2024, Viatris disclosed that “following an inspection by the U.S. FDA” at the Company’s manufacturing facility in Indore “the Agency has issued a Warning Letter, and an Import Alert related to this facility” which “affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted.”

Then, on February 27, 2025, Viatris released its fourth quarter and full year 2024 financial results, reporting, among other things, financial guidance metrics for fiscal year 2025 with “anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA.”

On this news, Viatris’ stock price fell $1.71, or 15.2%, to close at $9.53 per share on February 27, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Viatris’ efforts to downplay the ramifications of the Indore facility’s failed FDA inspection fell short of reality; (2) the impact to the Company’s projected fiscal year 2025 finances from the combination of the ongoing remediation efforts at the facility, the inability for the facility to manufacture and ship key products for the Company, particularly Lenalidomide, the inability for Viatris to convince the FDA to expand the exempt list to include such drugs, and an associated impact on shipments to other regions from the Indore facility was significant and resulted in much more than “a little bit” of a headwind; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us to Participate or Learn More:

If you purchased Viatris securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409558824/en/